期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 91, 期 6, 页码 1010-1021出版社
WILEY
DOI: 10.1038/clpt.2012.50
关键词
-
资金
- National Library of Medicine [1R01LM010016, 3R01LM010016-01S1, 3R01LM010016-02S1, 5T15-LM007079-19(HS)]
- National Center for Biomedical Ontology [U54-HG004028]
- i2b2 National Center for Biomedical Computing [2U54LM008748]
An important goal of the health system is to identify new adverse drug events (ADEs) in the postapproval period. Data-mining methods that can transform data into meaningful knowledge to inform patient safety have proven essential for this purpose. New opportunities have emerged to harness data sources that have not been used within the traditional framework. This article provides an overview of recent methodological innovations and data sources used to support ADE discovery and analysis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据